Pfizer expands label for blockbuster BRAF/MEK combo into lung cancer

Pfiz­er’s $11.4 bil­lion 2019 ac­qui­si­tion of Ar­ray Bio­Phar­ma and its can­cer drugs Braftovi and Mek­tovi is pay­ing off again, this time with an ex­pand­ed la­bel for metasta­t­ic non-small cell lung can­cer (NSCLC) with a BRAF V600E mu­ta­tion.

The FDA ap­proved the com­bi­na­tion of Braftovi (en­co­rafenib), a BRAF in­hibitor, and Mek­tovi (binime­tinib), a MEK in­hibitor, yes­ter­day af­ter­noon based on da­ta from the Phase II PHAROS study that in­ves­ti­gat­ed the com­bo ther­a­py in both treat­ment-naïve and pre­vi­ous­ly treat­ed pa­tients with the mu­tat­ed NSCLC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.